within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA15_Camazepam;

model Camazepam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 1.555555555555556e-05,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.013333333333333334,
    Tlag = 1200);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Camazepam</td></tr><tr><td>ATC code:</td><td>N05BA15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.8</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Camazepam is a benzodiazepine derivative primarily used for its anxiolytic, anticonvulsant, sedative, and muscle relaxant effects. It was previously used as an anxiolytic in some countries but is not widely approved or used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy volunteers, oral administration. No direct human clinical PK studies found in indexed literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05BA15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Camazepam;
